To include your compound in the COVID-19 Resource Center, submit it here.

Scholar Rock's niche

Scholar Rock raises $20 million for new class of drugs targeting growth factors

A $20 million series A financing will boost Scholar Rock Inc.'s discovery and development program for niche modulators, a class of compounds targeting growth factors in cell and tissue microenvironments. Arch Venture Partners, a new investor, led last week's round, joined by founding investors Polaris Partners and

Read the full 471 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers